Centre cuts MRPs on some trade-margin-capped cancer drugs
In short
The Centre reduced the maximum retail prices of some cancer medicines by as much as 93%. The report says some major brand-name drugs were not cut, and patient groups say some exclusions and missing data reduced the benefit.
This may make some treatment cheaper for patients. It is still not clear how many medicines were affected or how much relief patients will actually get.
What the reporting says
The Centre cut MRPs for some trade-margin-capped cancer medicines by up to 93%, according to the publisher-supplied summary. The report says major innovator brands saw no price reductions, and patient groups said exclusions under the patient-assistance programme and data gaps weakened the relief. The immediate effect is lower listed prices for some drugs, but the full scope of patient access gains remains unclear.
Why it matters
The Centre cut MRPs for some trade-margin-capped cancer medicines by up to 93%, based on the publisher-supplied summary. The report says major innovator brands were not reduced, while patient groups argued that exclusions from patient-assistance programmes and data gaps limited the benefit. The available reporting does not state the number of medicines covered or when the new prices take effect.